The vaccines from Johnson & Johnson and Verocel are being studied by the National Institute of Health (INS) for possible combined administration. The first clinical trial targets will be 360 unvaccinated people between 18 and 65 years of age in Mozambique's capital, Maputo.

The idea of using these vaccines in combination aims to identify more effective ways to protect people against a more severe manifestation of covid-19, according to ECOVA sub-investigator Patricia Ramgi.

According to the researcher, INS has already found four volunteers and about 50 are still under evaluation, since the campaign was launched and December last year.

The work is part of the second edition of the covid-19 Effectiveness and Safety Study (ECOVA), launched in December last year by the INS, whose aim is to provide more alternatives for immunization against the new coronavirus pandemic, without relying exclusively on a single type of vaccine.

Source: opais